Holbrook E. Kohrt
- Immunology top 0.2%
- Immune Cell Function and Interaction 55
- Immunotherapy and Immune Responses 50
- T-cell and B-cell Immunology 21
- Oncology top 0.5%
- CAR-T cell therapy research 52
- Cancer Immunotherapy and Biomarkers 33
- Hematology top 1%
- Hematopoietic Stem Cell Transplantation 17
- Genetics top 2%
-
- Lymphoma Diagnosis and Treatment 26
-
- Monoclonal and Polyclonal Antibodies Research 19
- Co-authors
- Ronald LevyAurélien MarabelleCariad ChesterRoch HouotIdit Sagiv-BarfiDebra K. CzerwinskiAsh A. AlizadehJoshua Brody
- Cited by
- ImmunologyOncologyHematology
- Journals
- Blood (44 papers)Journal for ImmunoTherapy of Cancer (12 papers)Clinical Cancer Research (7 papers)
- Partner nations
- United StatesFranceCanada
In The Last Decade
Holbrook E. Kohrt
145 papers receiving 7.7k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Immunology 4.7k
- Oncology 4.3k
- Hematology 768
- Genetics 543
- Pathology and Forensic Medicine 865
Countries citing papers authored by Holbrook E. Kohrt
This map shows the geographic impact of Holbrook E. Kohrt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holbrook E. Kohrt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holbrook E. Kohrt more than expected).
Fields of papers citing papers by Holbrook E. Kohrt
This network shows the impact of papers produced by Holbrook E. Kohrt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holbrook E. Kohrt. The network helps show where Holbrook E. Kohrt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Holbrook E. Kohrt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 76 | |
| 2 | 2016 | 179 | |
| 3 | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibodybreakdown → | 2016 | 281 |
| 4 | 2016 | 14 | |
| 5 | 2016 | 10 | |
| 6 | 2016 | 133 | |
| 7 | 2015 | 358 | |
| 8 | Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITKbreakdown → | 2015 | 352 |
| 9 | 2015 | 40 | |
| 10 | 2015 | 126 | |
| 11 | 2014 | 16 | |
| 12 | 2014 | 114 | |
| 13 | 2014 | 126 | |
| 14 | 2014 | 11 | |
| 15 | 2013 | 229 | |
| 16 | 2012 | 19 | |
| 17 | 2011 | 28 | |
| 18 | 2010 | 50 | |
| 19 | 2008 | 42 | |
| 20 | 2007 | 42 |
About Holbrook E. Kohrt
Holbrook E. Kohrt is a scholar working on Immunology, Oncology, Hematology, Pathology and Forensic Medicine and Genetics, having authored 147 papers that have together received 7.8k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (55 papers), CAR-T cell therapy research (52 papers), Immunotherapy and Immune Responses (50 papers), Cancer Immunotherapy and Biomarkers (33 papers), Lymphoma Diagnosis and Treatment (26 papers), T-cell and B-cell Immunology (21 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Hematopoietic Stem Cell Transplantation (17 papers). The work is most often cited by research in Immunology (4.7k citations), Oncology (4.3k citations), Hematology (768 citations), Genetics (543 citations) and Pathology and Forensic Medicine (865 citations). Holbrook E. Kohrt has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Ronald Levy, Aurélien Marabelle, Cariad Chester, Roch Houot, Idit Sagiv-Barfi, Debra K. Czerwinski, Ash A. Alizadeh, Joshua Brody, June H. Myklebust and Bruno C. Medeiros. Their work appears in journals such as Blood, Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, OncoImmunology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.